NDAORALSOLUTION
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
ELYXYB (celecoxib) by Inpharmus is cyclooxygenase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELYXYB is an oral liquid formulation of celecoxib, a cyclooxygenase inhibitor belonging to the nonsteroidal anti-inflammatory drug (NSAID) class. It is designed to treat pain and inflammation in patients who may benefit from an alternative dosage form to traditional solid tablets. The drug works by selectively inhibiting COX-2 enzymes, reducing prostaglandin production and inflammatory responses.
$0.6MPart D
Peak9.9 years to LOEThe product is at peak lifecycle stage with modest Part D penetration (531 claims, $604K spending in 2023), suggesting a niche market position with limited team expansion opportunities.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
Started Sep 2024
40 enrolled
Healthy Volunteer
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
Started Jun 2022
59 enrolled
Healthy Volunteers
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Started Jun 2022
25 enrolled
Colorectal Cancer
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Started Jan 2019
53 enrolled
Malignant Pleural Mesothelioma
Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.
Started Mar 2017
637 enrolled
Acute Post-surgical Pain
Worked on ELYXYB at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.